Progen Co (XKRX:296160) Capital Expenditure : ₩0.00 Mil (TTM As of . 20)

View and export this data going back to 2023. Start your Free Trial

What is Progen Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Progen Co's cash flow for capital expenditures for the six months ended in . 20 was ₩0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in . 20 was ₩0.00 Mil.

Progen Co Capital Expenditure Historical Data

The historical data trend for Progen Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progen Co Capital Expenditure Chart

Progen Co Annual Data

Trend

Capital Expenditure

Progen Co Semi-Annual Data

Capital Expenditure

Progen Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Capital Expenditure for the trailing twelve months (TTM) ended in . 20 was ₩0.00 Mil.

Progen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Magokjungang-ro, 7th Floor, Bio Innovation Park, Gangseo-gu, Seoul, KOR

Website

http://www.progen.co.kr

Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.

Progen Co Headlines

No Headlines